Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With Asthma (clinicaltrials.gov) - Oct 2, 2026 - P1 | N=120 | Not yet recruiting | Sponsor: Chiesi Farmaceutici S.p.A.
Adverse events • First-in-human • New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
|